Kiniksa Pharmaceuticals (NASDAQ:KNSA) Releases Earnings Results, Misses Expectations By $0.06 EPS

Kiniksa Pharmaceuticals (NASDAQ:KNSA) announced its quarterly earnings data on Tuesday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06), Zacks reports. The company had revenue of $122.50 million during the quarter, compared to analyst estimates of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm’s revenue was up 46.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.35 earnings per share.

Kiniksa Pharmaceuticals Trading Up 1.6 %

NASDAQ KNSA opened at $19.94 on Wednesday. Kiniksa Pharmaceuticals has a 1 year low of $16.56 and a 1 year high of $28.15. The company has a market cap of $1.44 billion, a P/E ratio of -142.38 and a beta of 0.32. The company has a fifty day simple moving average of $19.68 and a 200 day simple moving average of $22.59.

Analysts Set New Price Targets

KNSA has been the topic of a number of research reports. Wedbush restated an “outperform” rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Tuesday. Evercore ISI increased their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. raised their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $36.60.

Insider Activity

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 14,000 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $19.57, for a total transaction of $273,980.00. Following the completion of the transaction, the chief operating officer now owns 81,975 shares of the company’s stock, valued at $1,604,250.75. This represents a 14.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Mark Ragosa sold 8,969 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total value of $192,385.05. Following the sale, the chief financial officer now directly owns 22,958 shares of the company’s stock, valued at $492,449.10. This represents a 28.09 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 38,092 shares of company stock worth $745,589. Corporate insiders own 54.57% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.